Search clinical trials for: Arbaclofen Placarbil

Total 168 results

Indivior Inc.

Completed

A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers

Healthy Volunteers

United Kingdom
XenoPort, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States, Canada
XenoPort, Inc.

Completed

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

Back Pain

United States
XenoPort, Inc.

Completed

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

Multiple Sclerosis

United States
XenoPort, Inc.

Completed

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Gastroesophageal Reflux

United States
Indivior Inc.

Completed

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Alcohol Use Disorder

United States
Indivior Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

GERD

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Celso Arango, MD, PhD
UMC Utrecht

Completed

Arbaclofen in Children and Adolescents With ASD (AIMS2-CT1)

Autism Spectrum Disorder

Spain, United Kingdom, France
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Evdokia Anagnostou
McMaster University; Unity Health Toronto; University of Toronto; University of... and other collaborators

Active, not recruiting

Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) (ARBA)

Autism Spectrum Disorder

Canada
Seaside Therapeutics, Inc.

Terminated

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Gonzalez-Heydrich, Joseph, M.D.
Boston Children's Hospital; Seaside Therapeutics, Inc.

Terminated

TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers

Autism

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (Harbor-A)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Timothy Roberts
Simons Foundation; Clinical Research Associates, LLC

Completed

MEG Study of Acute STX209 Effects in ASD

Autism Disorder

United States
XenoPort, Inc.

Completed

A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

Muscle Spasticity

United States
RVL Pharmaceuticals, Inc.

Not yet recruiting

A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

Spasticity
Clinical Research Associates, LLC

Recruiting

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

16P11.2 Deletion Syndrome

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
Tanta University

Unknown

Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis

Liver Cirrhosis | Muscle Cramps

Egypt
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
University of Minnesota
Paralyzed Veterans of America Research Foundation

Completed

Oral and IV Baclofen in Adult Volunteers

Baclofen Withdrawal Syndrome

United States
Amsterdam UMC, location VUmc
Medtronic

Not yet recruiting

Predictive Factors for Succes of ITB in CP

Cerebral Palsy | Intrathecal Baclofen
Allaysis, LLC
University of Minnesota

Unknown

Repeated Dose IV Baclofen Safety/Bioequivalence Study

Intravenous Baclofen
Hospices Civils de Lyon

Not yet recruiting

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence (BABET)

Benzodiazepine Dependence

France
Tanta University

Recruiting

Baclofen in Preventing Postoperative Nausea and Vomiting After Bariatric Surgery

Morbid Obesity | Postoperative Nausea and Vomiting | Laparoscopic Sleeve Gastrectomy

Egypt
Vanderbilt University
Medtronic

Completed

Intrathecal (IT) Baclofen Drug Distribution (ITB)

Muscle Spasticity

United States
Shaare Zedek Medical Center

Terminated

Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?

Cerebral Palsy

Israel
Imperial College London
Medical Research Council

Completed

GABA-B Receptor Function in Healthy Volunteers

No Condition | Brain GABA-B Function

United Kingdom
Alkermes, Inc.

Completed

ALK29-002: A Study of Baclofen Formulations in Healthy Adults

Alcohol Dependence

United States
Centre for Addiction and Mental Health
Canadian Tobacco Control Research Initiative

Terminated

Baclofen for Smoking Cessation in a Non-Psychiatric Population (Baclofen)

Nicotine Dependence

Canada
Maastricht University
Medtronic

Completed

Dutch National ITB Study in Children With Cerebral Palsy

Cerebral Palsy | Spasticity

Netherlands
Azurity Pharmaceuticals

Completed

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Abuse Potential

United States
University of Alabama at Birmingham

Active, not recruiting

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

Analgesia | Acute Pain

United States
Piramal Critical Care, Ltd.

Completed

Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump

Severe Spasticity

United States
South West Sydney Local Health District
National Health and Medical Research Council, Australia; University of Sydney

Completed

Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease (BacALD)

Alcohol Dependence | Alcoholic Liver Disease

Australia
University of Texas Southwestern Medical Center
Tufts University

Completed

Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently

Pharmacokinetics

United States
University of Southern California

Completed

Does Reducing Spasticity Permit an Increase in Strength?

Spastic Diplegic Cerebral Palsy

United States
University of Minnesota
Paralyzed Veterans of America Research Foundation

Completed

Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers

Safety and Pharmacokinetics of Intravenous Baclofen

United States
MedtronicNeuro

Completed

SISTERS: Spasticity In Stroke Study - Randomized Study (SISTERS)

Severe Spasticity

Belgium, Spain, United States, Austria, Germany, Italy, Netherlands, Slovenia, United Kingdom
University of Pittsburgh

Completed

Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia

Trigeminal Neuralgia

United States

Search clinical trials for: Arbaclofen Placarbil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations